Mirtazapine Sandoz 30mg 20 tablets — Made in Germany — Free Delivery

Treatment of conditions of deep depression.

Hypersensitivity to mirtazapine or to any other component of the preparation.

Simultaneous use of mirtazapine with MAO inhibitors (MAO).

active ingredient: mirtazapine;

1 tablet contains mirtazapine 15 mg or 30 mg

excipients: tablet core - lactose, corn starch, hydroxypropyl cellulose, colloidal silicon dioxide, magnesium stearate

tablets of 15 mg shell (opadry yellow) - hydroxypropyl methylcellulose, titanium dioxide (E 171), polyethylene glycol 8000, iron oxide yellow (E 172), quinoline yellow (E 104), sunset yellow FCF (E 110)

tablets of 30 mg shell (opadri beige) - hydroxypropyl methylcellulose, titanium dioxide (E 171), polyethylene glycol 8000, iron oxide red (E172), iron oxide yellow (E172), iron oxide black (E172)

Adults. The effective daily dose is usually from 15 to 45 mg, the initial dose is 15 or 30 mg. Mirtazapine begins to show an effect in general after 1-2 weeks of treatment. Treatment with an adequate dose will cause a positive response within 2-4 weeks. If there is insufficient response, the dose may be increased. If no effect is observed within the next 2-4 weeks, the preparation  should be discontinued.

Elderly patients. The recommended dose is the same as for adults. In order to achieve a satisfactory and safe result, an increase in the dose for elderly patients is carried out under the supervision of a physician.

Dosage for impaired renal function. Mirtazapine clearance may decrease in patients with moderate or severe renal insufficiency (creatinine clearance <40 ml/min). When prescribing the preparation to this category of patients, creatinine clearance should be monitored.

Dosing in hepatic insufficiency. The clearance of mirtazapine may be reduced in patients with hepatic impairment. This fact should be taken into account when prescribing the preparation to this category of patients, especially with severe liver failure. Treatment should be started with a minimum dose, controlling the clearance of mirtazapine, especially when the dose is increased.

The half-life of mirtazapine is 20-40 hours, so it can be used once a day. It is advisable to use the preparation once at night before going to bed. The daily dose can be divided into 2 doses (morning and evening; the larger dose should be taken at night).

Tablets should be taken orally, swallowed without chewing; if necessary, drink water.

Patients with depression should be treated for a long time, at least 6 months, until the symptoms disappear completely.

It is recommended to stop treatment with mirtazapine gradually to avoid withdrawal symptoms.

Children.

The preparation should not be used to treat children. Suicide-related behavior (suicide attempts and suicidal thoughts) and hostility (predominantly aggression, oppositional behavior and anger) were more frequently observed among children and adolescents treated with antidepressants. If, based on clinical need, treatment is initiated, the patient should be closely monitored for the occurrence of suicidal symptoms. In addition, long-term safety data in children and adolescents on growth, maturation, cognitive and behavioral development are not available.